[1] Polaris Observatory Collaborators. Global prevalence, treat-ment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol, 2018, 3: 383-403.
[2] Wu W, Zhu Y, Yu C, et al. Clinical features of treatment-naive patients with hepatitis B virus infection: a community-based survey from high-and intermediate-hepatitis B endemicity regions in Southeast China. Medicine (Baltimore), 2017, 96: e6660.
[3] Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate-clinical pharmacology and pharmacokinetics. Clin Pharmacokinet, 2004, 43:595-612.
[4] Giesler KE, Liotta DC. Next-generation reduction sensitive lipid conjugates of Tenofovir: antiviral activity and mechanism of release. J Med Chem, 2016, 59: 10244-10252.
[5] Ruane PJ, DeJesus E, Berger D,et al. Antiviral activity,safety,and pharmacokinetics/pharmacodynamics of tenofovir alafe-namide as 10-day monotherapy in hiv-1-positive adults. J Acquired Immune Defic Syndr, 2013, 63: 449-455.
[6] Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov, 2003, 2: 812-822.
[7] Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir neph-rotoxicity: acute tubular necrosis with distinctive clinical,pathological,and mitochondrial abnormalities. Kidney Int, 2010, 78: 1171-1177.
[8] Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety,antiviral activity,and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol, 2015, 62:533-540.
[9] Chan HL, Fung S, Seto WK,et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection:a randomised, double-blind,phase 3,non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1:185-195.
[10] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised,double-blind,phase 3,non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1:196-206.
[11] Chan HL,Lim YS,Seto WK,et al. Three year efficacy and safety of tenofovir alafenamide(taf) compared to tenofovir disoproxil fumarate(tdf) in HBeAg-negative and HBeAg-positive patients with chronic hepatitis B. AASLD 2018, Poster 381.
[12] Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF),each cofor-mulated with elvitegravir,cobicistat,and emtricitabine (E/C/F) for initial hiv-1 treatment: week 144 results. J Acquir Immune Defic Syndr, 2017, 75:211-218.
[13] Chuang WL, Agarwal KH, Wang JS, et al. Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks. J Hepatol, 2017, 66:S695.
[14] Fung S, Chuang WL, Nishiguchi S, et al. Smaller decreases in bone mineral density in chronic hepatitis B patients receiving tenofovir alafenamide compared with tenofovir disoproxil fumarate over 96 weeks. J Hepatol, 2017, 66:S691-692.
[15] Seto WK, Asahina Y, Brown TT, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection. Clin Gastroenterol Hepatol, 2018, pii: S1542-3565(18)30633-30635.
[16] Wai K, Walter S, Maria B, et al. Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide(TAF) from tenofovir disoproxil fumarate(TDF). AASLD, 2018, Poster 404.
[17] Chan HL, Fung S, Seto WK, et al. Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 trials in HBeAg-positive and HBeAg-neagtive patients with chronic hepatitis B. J Hepatol,2017,66:S25.
[18] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol, 2017, 67:370-398.
[19] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken), 2018, 12:33-34. |
